GlassScriptPhysician profile
Florena Ponce
NPI 1518614619
$1,801.70
in general payments reported to CMS, 2019-2025
23 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $908 · 2023: $318 · 2024: $389 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Education: $91.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.90 |
| Education | $91.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $334.92 | 2022-2025 | Padcev |
| Exelixis INC. | $285.61 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $223.98 | 2022-2024 | Padcev |
| Merck Sharp & Dohme LLC | $132.13 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $126.03 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $106.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $95.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $88.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.36 | 2022-2023 | |
| Incyte Corporation | $43.10 | 2022 | |
| Amgen INC. | $43.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.18 | 2022 | |
| Janssen Biotech, INC. | $35.17 | 2022 | |
| Genentech USA, INC. | $30.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $25.08 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.45 | 2022 | |
| Lilly USA, LLC | $23.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.43 | 2022 | |
| Eisai INC. | $19.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.30 | 2022 | |
| Celgene Corporation | $16.98 | 2022 | |
| Taiho Oncology, INC. | $15.23 | 2022 | |
| Kyowa Kirin, INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florena Ponce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.